CCM
BTAI icon

CAAS Capital Management’s BioXcel Therapeutics BTAI Stock Holding History

CAAS Capital Management’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-14,518
Closed -$6.75M – 957
2021
Q2 		$6.75M Buy
+14,518
New +$7.91M 0.11% 194

Other funds holding BTAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AIM
Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

CAAS Capital Management's BTAI Position: Q3 2021 in Review

CAAS Capital Management sold out of BioXcel Therapeutics (BTAI) in Q3 2021, closing a stake of 14,518 shares — an estimated $6.75M sold.

CAAS Capital Management first reported a position in BTAI in Q2 2021 and held it in 1 quarter. The position peaked at $6.75M in Q2 2021. 103 funds tracked by Wall St. Rank hold BTAI as of Q3 2021.

  • CAAS Capital Management reported no remaining BioXcel Therapeutics position as of Q3 2021 after selling out during the quarter.
  • CAAS Capital Management sold 14,518 BioXcel Therapeutics shares in Q3 2021, an estimated $6.75M.
  • CAAS Capital Management first reported a position in BioXcel Therapeutics in Q2 2021 and held it in 1 quarter.
  • CAAS Capital Management's BioXcel Therapeutics position peaked at $6.75M in Q2 2021.
  • 103 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q3 2021.

Based on CAAS Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.